Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

$526.19 +3.81 (+0.73%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$523.65 -2.54 (-0.48%)

As of 09/25/2026 07:59 PM Eastern

Compare

Vertex Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 23 Analyst Ratings

Sell
0

Hold
2

Buy
21

Based on 23 Wall Street analysts who have issued ratings for Vertex Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 2 have given a hold rating, 20 have given a buy rating, and 1 has given a strong buy rating for VRTX.

Consensus Price Target

$573.83
9.05% Upside

According to the 23 analysts' twelve-month price targets for Vertex Pharmaceuticals, the average price target is $573.83. The highest price target for VRTX is $665.00, while the lowest price target for VRTX is $442.00. The average price target represents a forecasted upside of 9.05% from the current price of $526.19.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for VRTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Vertex Pharmaceuticals and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VRTX Analyst Ratings Over Time

Type	Current Forecast 9/27/25 to 9/27/26	1 Month Ago 8/28/25 to 8/28/26	3 Months Ago 6/29/25 to 6/29/26	1 Year Ago 9/27/24 to 9/27/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	20 Buy rating(s)	20 Buy rating(s)	22 Buy rating(s)	15 Buy rating(s)
Hold	2 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	12 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$573.83	$563.50	$555.91	$493.81
Forecasted Upside	9.05% Upside	4.03% Upside	11.26% Upside	28.02% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

VRTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VRTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Vertex Pharmaceuticals Stock vs. The Competition

Type	Vertex Pharmaceuticals	Healthcare Companies	Broader Market
Consensus Rating Score	2.96	2.31	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	9.05% Upside	764.10% Upside	19.20% Upside
News Sentiment Rating	Positive News See Recent VRTX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/21/2026	Leerink Partners 2 of 5 stars		Initiated Coverage	Outperform	$594.00	+17.18%
9/11/2026	JPMorgan Chase & Co. 3 of 5 stars	Jessica Fye 4 of 5 stars	Reiterated Rating	Overweight	$515.00 ➝ $560.00	+8.83%
9/10/2026	Weiss Ratings 5 of 5 stars		Upgrade	Buy (B-) ➝ Buy (B)
9/1/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terence Flynn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Overweight	$665.00	+21.43%
9/1/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$653.00	+19.92%
8/5/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Brill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$560.00 ➝ $565.00	+15.85%
8/5/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eliana Merle Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$615.00 ➝ $617.00	+28.89%
8/4/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Phil Nadeau Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$525.00 ➝ $550.00	+16.84%
8/4/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$500.00	+2.81%
8/4/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Whitney Ijem Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$436.00 ➝ $442.00	-6.10%
Get the Latest News and Ratings for VRTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
8/4/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Carter Gould Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$590.00 ➝ $595.00	+26.40%
7/29/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Pickering Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
7/13/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Yee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$545.00 ➝ $585.00	+21.41%
7/7/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$543.00 ➝ $570.00	+7.63%
3/18/2026	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Naz Rahman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$575.00	+24.33%
3/10/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ying Huang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$571.00 ➝ $598.00	+18.47%
3/10/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$575.00 ➝ $585.00	+16.38%
3/10/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Akash Tewari Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$580.00	+25.85%
3/10/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jay Olson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$540.00 ➝ $600.00	+30.19%
3/10/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Fein Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$591.00 ➝ $641.00	+39.08%
2/13/2026	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Louise Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$495.00 ➝ $558.00	+12.34%
1/23/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Liisa Bayko Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$475.00 ➝ $530.00	+13.41%
1/6/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andy Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$548.00	+22.10%
12/10/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$460.00 ➝ $515.00	+15.74%
9/2/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Brill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Market Perform
8/6/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Debjit Chattopadhyay Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$558.00 ➝ $546.00	+40.91%
8/5/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evan David Seigerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Outperform	$557.00 ➝ $530.00	+12.22%
5/23/2025	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Hans Engel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/6/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
5/6/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Stringer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold
1/27/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christopher Raymond Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$535.00 ➝ $533.00	+20.72%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 06:47 PM ET.

Should I Buy Vertex Pharmaceuticals Stock? VRTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 25, 2026. Please send any questions or comments about these Vertex Pharmaceuticals pros and cons to contact@marketbeat.com.

Vertex Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Vertex Pharmaceuticals Incorporated:

Vertex Pharmaceuticals Incorporated reported positive Phase 2b data for inaxaplin in patients with APOL1-mediated kidney disease, a significant expansion beyond its core cystic fibrosis business that has attracted analyst attention and suggests new growth engines in the kidney disease sector.
The stock is currently trading at $526.19, which is below the consensus price target of $573.83 from analysts who maintain a Moderate Buy rating, indicating potential upside as the market digests recent clinical successes and pipeline diversification.
Vertex Pharmaceuticals Incorporated demonstrated strong financial performance in the most recent quarter with revenue of $3.33 billion, exceeding analyst estimates of $3.23 billion and representing a 12.5% year-over-year increase, highlighting robust commercial execution.
Analyst sentiment has improved recently, with TD Cowen raising its price target to $550 and Leerink Partners initiating coverage with an Outperform rating and a $594 price objective, reflecting increased confidence in the company's long-term growth prospects.
The company has a low beta of 0.32, suggesting that Vertex Pharmaceuticals Incorporated shares may offer lower volatility compared to the broader market, which can be appealing to investors seeking stability in their biotechnology holdings.

Vertex Pharmaceuticals
Bear Case

Investors should be bearish about investing in Vertex Pharmaceuticals Incorporated for these reasons:

Vertex Pharmaceuticals Incorporated recently missed its earnings per share consensus estimate by $0.01 in the latest quarter, reporting $4.73 against an expected $4.74, which may signal challenges in maintaining consistent profitability growth despite revenue beats.
There has been significant insider selling activity, with multiple executives including the CMO and EVPs selling shares in recent months, such as Carmen Bozic selling over 10,000 shares in May and June 2026, which can be interpreted as a lack of confidence in near-term stock appreciation.
The company's price-to-earnings ratio stands at 30.63, which is relatively high and may limit upside potential if growth slows, especially given that the stock has already risen significantly from its 52-week low of $379.72 to its current level.
Vertex Pharmaceuticals Incorporated does not pay a dividend, with a yield of 0.00%, which may be a drawback for income-focused investors who prefer regular cash flow from their equity investments.
Short interest has increased slightly in recent months, with shares shorted rising to 4,716,867 as of September 15, 2026, indicating that some market participants are betting against the stock's future performance.

VRTX Forecast - Frequently Asked Questions

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Vertex Pharmaceuticals is $573.83, with a high forecast of $665.00 and a low forecast of $442.00.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. There are currently 2 hold ratings, 20 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VRTX shares.

According to analysts, Vertex Pharmaceuticals's stock has a predicted upside of 9.05% based on their 12-month stock forecasts.

Over the previous 90 days, Vertex Pharmaceuticals's stock had 4 upgrades and 2 downgrades by analysts.

Vertex Pharmaceuticals has been rated by research analysts at Barclays, Canaccord Genuity Group, Cantor Fitzgerald, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Royal Bank Of Canada, Sanford C. Bernstein, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Truist Financial, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like Vertex Pharmaceuticals more than other "healthcare" companies. The consensus rating for Vertex Pharmaceuticals is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how VRTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Vertex Pharmaceuticals Recommendations

MarketBeat monitors more than a dozen sources for Vertex Pharmaceuticals analyst ratings, with the most recent rating issued on 9/21/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target